Safety, tolerance, and pharmacokinetics of amphotericin B lipid complex in children with hepatosplenic candidiasis

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 9, 1997, Pages 1944-1948

  Walsh, Thomas J ^a,b   Whitcomb, Patricia ^a,b   Piscitelli, Stephen ^c   Figg, William D ^a   Hill, Suvimol ^c   Chanock, Stephen J ^a   Jarosinski, Paul ^c   Gupta, Renu ^d   Pizzo, Philip A ^a,e  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d BRISTOL MYERS SQUIBB   (United States)

^e BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX;

ADOLESCENT; AREA UNDER THE CURVE; ARTICLE; CANCER PATIENT; CANDIDIASIS; CHILD; CLINICAL ARTICLE; DOSE LIVER FUNCTION RELATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERANCE; FEMALE; FEVER; HEADACHE; HEPATITIS; HUMAN; HYPOKALEMIA; HYPOMAGNESEMIA; INTRAVENOUS DRUG ADMINISTRATION; MALE; NAUSEA; PRIORITY JOURNAL;

EID: 0030765063     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.9.1944     Document Type: Article

References (28)

1. Anaissie, E., G. P. Bodey, H. Kantarjian, C. David, K. Barnett, E. Bow, R. Defelice, N. Downs, T. File, G. Karam, et al. 1991. Fluconazole therapy tor chronic disseminated candidiasis in patients with leukemia and prior amphotericin B therapy. Am. J. Med. 91:142-150.
2. Anaissie, E. J., M. White, O. Uzun, C. Singer, G. P. Bodey, D. Matzke, N. Azarina, and G. Lopez-Berestein. 1995. Amphotericin B lipid complex versus amphotericin B for treatment of hematogenous and invasive candidiasis: a prospective, randomized, multicenter trial, abstr. LM21, p. 330. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
3. Benson, J. M., and M. C. Nahata. 1989. Pharmacokinetics of amphotericin B in children. Antimicrob. Agents Chemother. 33:1989-1993.
4. Evans, T. G., J. Mayer, S. Cohen, D. Classen, and K. Carroll. 1991. Fluconazole failure in the treatment of invasive mycoses. J. Infect. Dis. 164:1232-1235.
5. Flynn, P. M., N. M. Marina, G. K. Rivera, and W. T. Hughes. 1993. Candida tropicalis infections in children with leukemia. Leuk. Lymphoma 10:369-376
6. Gibaldi, M., and D. Perrier. 1982. Pharmacokinetics, 2nd ed. Marcel Dekker, New York, N.Y.
7. Hiemenz, J. W., J. Lister, and E. J. Anaissie. 1995. Emergency-use amphotericin B lipid complex (ABLC) in the treatment of patients with aspergillosis: historical control comparison with amphotericin B. Blood 86(Suppl. 1):849a. (Abstract.)
8. Hiemenz, J. W., and T. J. Walsh. 1996. Lipid formulations of amphotericin B: recent progress and future directions. Clin. Infect. Dis. 22(Suppl. 2):S133-S144.
9. Janoff, A. S., L. T. Boni, M. C. Popescu, S. R. Minchey, P. R. Cullis, T. D. Madden, T. Taraschi, S. M. Gruner, E. Shyamsunder, and M. W. Tate. 1988. Unusual lipid structures selectively reduce the toxicity of amphotericin B. Proc. Natl. Acad. Sci. USA 85:6122-6126.
10. Kan, V. L., J. E. Bennett, M. A. Amantea, M. C. Smolskis, E. McManus, D. M. Grasela, and J. W. Sherman. 1991. Comparative safety, tolerance, and pharmacokinetics of amphotericin B lipid complex and amphotericin B desoxycholate in healthy male volunteers. J. Infect. Dis. 164:418-421.
11. Kauffman, C. A., S. F. Bradley, S. C. Ross, and D. R. Weber. 1991. Hepatosplenic candidiasis: successful treatment with fluconazole. Am. J. Med. 91:137-141.
12. Koren, G., A. Lau, J. Klein, C. Golas, M. Bologa-Campeanu, S. Soldn, S. M. MacLeod, and C. Prober. 1988. Pharmacokinetics and adverse effects of amphotericin B in infants and children. J. Pediatr. 113:559-563.
13. Lee, J., M. Allende, A. Francesconi, T. Sein, H. Dollenberg, K. Garrett, C. Lyman, P. Francis, P. Pizzo, and T. Walsh. 1992. Reticuloendothelial loading with ABLC is effective against chronic disseminated candidiasis in rabbits, ahstr. 52. The 7th International Symposium on Infections in the Immunocompromised Host.
14. Levine, S. J., T. J. Walsh, A. Martinez, P. Q. Eichacker, G. Lopez-Berestein, and C. Natanson. 1991. Hypoxemia, pulmonary hypertension, and depression of cardiac output as sequelae of liposomal amphotericin B infusion. Ann. Intern. Med. 114:664-666.
15. Lopez-Berestein, G., G. P. Bodey, L. S. Frankel, and K. Mehta. 1987. Treatment of hepatosplenic candidiasis with liposomal amphotericin B. J. Clin. Oncol. 5:310-317.
16. MacDonald, J., D. Haller, and R. Mayer. 1995. Manual of oncologic therapeutics, 3rd ed., p. 519-523. J. B. Lippincott Co., Philadelphia, Pa.
17. Miller, J. H., L. D. Greenfield, and B. R. Wald. 1982. Candidiasis of the liver and spleen in childhood. Pediatr. Radiol. 142:375-380.
18. Perkins, W. R., S. R. Minchey, L. T. Boni, C. E. Swenson, M. C. Popescu, R. F. Pasternack, and A. S. Janoff. 1992. Amphotericin B-phospholipid interactions responsible for reduced mammalian cell toxicity. Biochim. Biophys. Acta 1107:271-282.
19. Ringdén, O., and J. Tollemar. 1993. Liposomal amphotericin B (AmBisome®) treatment of invasive fungal infections in immunocompromised children. Mycoses 36:187-192.
20. Starke, J. R., O. Mason, W. G. Kramer, and S. L. Kaplan. 1987. Pharmacokinetics of amphotericin B in infants and children. J. Infect. Dis. 155:766-774.
21. Tashjian, L. S., J. S. Abramson, and J. E. Peacock, Jr. 1984. Focal hepatic candidiasis: a distinct clinical variant of candidiasis in immunocompromised patients. Rev. Infect. Dis. 6:689-703.
22. Thaler, M., B. Pastakia, T. H. Shawker, T. O'Leary, and P. A. Pizzo. 1988. Hepatic candidiasis in cancer patients: the evolving picture of the syndrome. Ann. Intern. Med. 108:88-100.
23. von Eiff, M., A. Fahrenkamp, N. Ross, W. Fegeler, and J. van de Loo. 1990. Hepatosplenic candidiasis - a late manifestation of Candida septicemia. Mycoses 33:283-290.
24. Walsh, T. J., K. Garrett, E. Feuerstein, M. Girton, M. Allende, J. Bacher, A. Francesconi, R. Schaufele, and P. A. Pizzo. 1995. Therapeutic monitoring of experimental invasive pulmonary aspergillosis by ultrafast computerized tomography, a novel, noninvasive method for measuring responses to antifungal therapy. Antimicrob. Agents Chemother. 39:1065-1069.
25. Walsh, T. J., C. Gonzalez, C. A. Lyman, S. Chanock, and P. A. Pizzo. 1995. Invasive fungal infections in children: recent advances in diagnosis and treatment. Adv. Pediatr. Infect. Dis. 11:187-290.
26. Walsh, T. J., J. W. Hiemenz, N. Seibel, and E. J. Anaissie. 1994. Amphotericin B lipid complex in the treatment of 228 cases of invasive mycosis, abstr. M69, p. 247. In Abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
27. Walsh, T. J., P. O. Whitcomb, S. Ravankar, K. Shannon, S. Alish, and P. A. Pizzo. 1995. Successful treatment of hepatosplenic candidiasis through repeated episodes of neutropenia. Cancer 76:2357-2362.
28. Wiley, J. M., N. Smith, B. Lenethal, M. L. Graham, L. C. Strauss, C. A. Hurwitz, J. Modlin, D. Mellits, R. Baumgardner, B. J. Corden, and C. I. Civin. 1990. Invasive fungal disease in pediatric leukemia patients with fever and neutropenia during induction chemotherapy. A multivariate analysis of risk factors. J. Clin. Oncol. 8:280-286.